Kazia Therapeutics Ltd
Research Kazia Therapeutics Ltd (KZIA) on Bullrun: market cap USD 157.58M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKZIA
- ExchangeNASDAQ
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 157.58M
- Financial periodQ4 2025
Valuation Snapshot
latest market cap is USD 157.58M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 157.58M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 78.11M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 8.56M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 11.60M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 9.22M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 111.19M | n/a | n/a | n/a |
About Kazia Therapeutics Ltd
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kazia Therapeutics Ltd's market cap?
Kazia Therapeutics Ltd's market capitalization is USD 157.58M.
What does Kazia Therapeutics Ltd do?
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel.